Pfizer's $1B protein degradation bet yields 3% response rate in Arvinas' midphase breast cancer trial

Pfizer’s $1 billion bet on Arvinas’ protein degradation technology has delivered phase 2 data. After a publication snafu, Arvinas posted the breast cancer results ahead of schedule—and revealed one partial response among 35 patients at its phase 3 dose.